Titre : Aldose-ketose isomerases

Aldose-ketose isomerases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatitis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Aldose-ketose isomerases : Questions médicales les plus fréquentes", "headline": "Aldose-ketose isomerases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Aldose-ketose isomerases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-15", "dateModified": "2025-02-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Aldose-ketose isomerases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Intramolecular oxidoreductases", "url": "https://questionsmedicales.fr/mesh/D019746", "about": { "@type": "MedicalCondition", "name": "Intramolecular oxidoreductases", "code": { "@type": "MedicalCode", "code": "D019746", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.399.475" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Glucose 6-phosphate isomerase", "alternateName": "Glucose-6-Phosphate Isomerase", "url": "https://questionsmedicales.fr/mesh/D005956", "about": { "@type": "MedicalCondition", "name": "Glucose 6-phosphate isomerase", "code": { "@type": "MedicalCode", "code": "D005956", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.399.475.200.350" } } }, { "@type": "MedicalWebPage", "name": "Mannose 6-phosphate isomerase", "alternateName": "Mannose-6-Phosphate Isomerase", "url": "https://questionsmedicales.fr/mesh/D008359", "about": { "@type": "MedicalCondition", "name": "Mannose 6-phosphate isomerase", "code": { "@type": "MedicalCode", "code": "D008359", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.399.475.200.550" } } }, { "@type": "MedicalWebPage", "name": "Triose phosphate isomerase", "alternateName": "Triose-Phosphate Isomerase", "url": "https://questionsmedicales.fr/mesh/D014305", "about": { "@type": "MedicalCondition", "name": "Triose phosphate isomerase", "code": { "@type": "MedicalCode", "code": "D014305", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.399.475.200.775" } } } ], "about": { "@type": "MedicalCondition", "name": "Aldose-ketose isomerases", "alternateName": "Aldose-Ketose Isomerases", "code": { "@type": "MedicalCode", "code": "D019747", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Francesco Balestri", "url": "https://questionsmedicales.fr/author/Francesco%20Balestri", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Roberta Moschini", "url": "https://questionsmedicales.fr/author/Roberta%20Moschini", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Umberto Mura", "url": "https://questionsmedicales.fr/author/Umberto%20Mura", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Mario Cappiello", "url": "https://questionsmedicales.fr/author/Mario%20Cappiello", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Zijie Li", "url": "https://questionsmedicales.fr/author/Zijie%20Li", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology , Jiangnan University , Wuxi , Jiangsu 214122 , People's Republic of China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Post-prostatic-massage urine exosomes of men with chronic prostatitis/chronic pelvic pain syndrome carry prostate-cancer-typical microRNAs and activate proto-oncogenes.", "datePublished": "2022-11-17", "url": "https://questionsmedicales.fr/article/36321189", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/1878-0261.13329" } }, { "@type": "ScholarlyArticle", "name": "Effects of low-intensity pulsed ultrasound on the microorganisms of expressed prostatic secretion in patients with IIIB prostatitis.", "datePublished": "2024-07-04", "url": "https://questionsmedicales.fr/article/38965410", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-66329-x" } }, { "@type": "ScholarlyArticle", "name": "Preclinical models and evaluation criteria of prostatitis.", "datePublished": "2023-05-09", "url": "https://questionsmedicales.fr/article/37228599", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1183895" } }, { "@type": "ScholarlyArticle", "name": "Chronic prostatitis as possible risk factor for Peyronie's disease: Psychological, sexual and prostatitis-like symptoms in patients with PD.", "datePublished": "2023-05-31", "url": "https://questionsmedicales.fr/article/37259816", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4081/aiua.2023.11406" } }, { "@type": "ScholarlyArticle", "name": "How I manage bacterial prostatitis.", "datePublished": "2022-06-13", "url": "https://questionsmedicales.fr/article/35709903", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cmi.2022.05.035" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Isomerases", "item": "https://questionsmedicales.fr/mesh/D007535" }, { "@type": "ListItem", "position": 5, "name": "Intramolecular oxidoreductases", "item": "https://questionsmedicales.fr/mesh/D019746" }, { "@type": "ListItem", "position": 6, "name": "Aldose-ketose isomerases", "item": "https://questionsmedicales.fr/mesh/D019747" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Aldose-ketose isomerases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Aldose-ketose isomerases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Aldose-ketose isomerases", "description": "Comment diagnostiquer une déficience en aldose-kétose isomérases ?\nQuels tests sont utilisés pour évaluer l'activité des isomérases ?\nLes symptômes peuvent-ils indiquer un problème d'isomérases ?\nY a-t-il des marqueurs biologiques spécifiques ?\nComment les tests génétiques aident-ils au diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D019747?mesh_terms=Prostatitis&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Aldose-ketose isomerases", "description": "Quels sont les symptômes d'une déficience en isomérases ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes neurologiques associés ?\nComment les symptômes affectent-ils la qualité de vie ?\nLes symptômes sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D019747?mesh_terms=Prostatitis&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Aldose-ketose isomerases", "description": "Peut-on prévenir les déficiences en isomérases ?\nY a-t-il des conseils diététiques préventifs ?\nLes antécédents familiaux influencent-ils la prévention ?\nLe dépistage génétique est-il recommandé ?\nComment l'éducation peut-elle aider à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D019747?mesh_terms=Prostatitis&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Aldose-ketose isomerases", "description": "Quels traitements sont disponibles pour cette condition ?\nLes médicaments peuvent-ils aider à gérer les symptômes ?\nLa thérapie génique est-elle une option ?\nComment un régime alimentaire aide-t-il ?\nY a-t-il des traitements expérimentaux ?", "url": "https://questionsmedicales.fr/mesh/D019747?mesh_terms=Prostatitis&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Aldose-ketose isomerases", "description": "Quelles complications peuvent survenir ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la santé globale ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être évitées ?", "url": "https://questionsmedicales.fr/mesh/D019747?mesh_terms=Prostatitis&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Aldose-ketose isomerases", "description": "Quels sont les facteurs de risque connus ?\nL'âge joue-t-il un rôle dans les facteurs de risque ?\nLes facteurs environnementaux influencent-ils le risque ?\nY a-t-il des tests pour évaluer les facteurs de risque ?\nComment le mode de vie affecte-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D019747?mesh_terms=Prostatitis&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en aldose-kétose isomérases ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques et des analyses génétiques peuvent confirmer la déficience." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des isomérases ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques mesurant l'activité enzymatique dans des échantillons de sang ou d'urine." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils indiquer un problème d'isomérases ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes métaboliques peuvent suggérer une anomalie dans l'activité des isomérases." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs biologiques spécifiques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de certains sucres dans le sang peuvent servir de marqueurs." } }, { "@type": "Question", "name": "Comment les tests génétiques aident-ils au diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Ils identifient des mutations spécifiques dans les gènes codant pour les isomérases." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en isomérases ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent hypoglycémie, troubles digestifs et retard de croissance." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent apparaître dès la naissance ou plus tard dans l'enfance." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques peuvent survenir en raison de déséquilibres métaboliques." } }, { "@type": "Question", "name": "Comment les symptômes affectent-ils la qualité de vie ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent entraîner des limitations dans l'alimentation et des problèmes de santé chroniques." } }, { "@type": "Question", "name": "Les symptômes sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent être gérés, mais d'autres peuvent persister sans traitement." } }, { "@type": "Question", "name": "Peut-on prévenir les déficiences en isomérases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un dépistage néonatal peut aider à identifier les cas précoces." } }, { "@type": "Question", "name": "Y a-t-il des conseils diététiques préventifs ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter certains sucres peut réduire le risque de complications chez les porteurs de mutations." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de troubles métaboliques augmentent le risque." } }, { "@type": "Question", "name": "Le dépistage génétique est-il recommandé ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage génétique peut être conseillé pour les familles à risque d'anomalies enzymatiques." } }, { "@type": "Question", "name": "Comment l'éducation peut-elle aider à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation sur les symptômes et les risques peut aider à une détection précoce." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour cette condition ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut des régimes alimentaires spécifiques et des suppléments enzymatiques." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider à gérer les symptômes ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments peuvent être prescrits pour traiter les symptômes associés, comme l'hypoglycémie." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche, mais pas encore une option standard pour ces déficiences." } }, { "@type": "Question", "name": "Comment un régime alimentaire aide-t-il ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Un régime adapté peut réduire les symptômes en limitant les sucres problématiques." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des essais cliniques explorent de nouvelles approches, mais leur efficacité n'est pas encore prouvée." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles métaboliques graves et des problèmes de développement." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la santé globale ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent entraîner des problèmes de santé chroniques et affecter la qualité de vie." } }, { "@type": "Question", "name": "Y a-t-il des risques de complications à long terme ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme peuvent survenir sans traitement approprié." } }, { "@type": "Question", "name": "Les complications peuvent-elles être évitées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une gestion proactive des symptômes peut réduire le risque de complications graves." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque connus ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux et certaines mutations génétiques." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans les facteurs de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains facteurs de risque sont plus fréquents chez les nourrissons et les jeunes enfants." } }, { "@type": "Question", "name": "Les facteurs environnementaux influencent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs environnementaux peuvent interagir avec des prédispositions génétiques." } }, { "@type": "Question", "name": "Y a-t-il des tests pour évaluer les facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent identifier des mutations associées à un risque accru." } }, { "@type": "Question", "name": "Comment le mode de vie affecte-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut réduire le risque de complications liées aux déficiences enzymatiques." } } ] } ] }

Sources (10000 au total)

Chronic prostatitis as possible risk factor for Peyronie's disease: Psychological, sexual and prostatitis-like symptoms in patients with PD.

This study aims to investigate a possible relationship between chronic prostatitis (CP) and Peyronie's disease (PD) and to characterize the psychological profile of patients suffering from PD, with or... We included 539 patients with PD, of which 200 were found to have underlying CP. As a comparator population, we selected 2201 patients without PD, referring to our tertiary care clinic. In this popula... The overall prevalence of chronic prostatitis in PD patients was 37.1% compared to a prevalence of 17.4% in the non-PD control population (OR = 2.79 and p < 0.0001). The severity of CP symptom total s... Chronic prostatitis (CP) and Peyronie's disease (PD) are frequently associated. Our results demonstrate the strong impact of chronic prostatitis on the mental status of PD patients. Anxiety and depres...

How I manage bacterial prostatitis.

Bacterial prostatitis is a highly prevalent infection responsible for significant morbidity among men. The diagnosis and treatment for bacterial prostatitis remains complicated. The difficulty in diag... We aimed to provide a useful resource for clinicians in effectively diagnosing and managing acute bacterial prostatitis (ABP) and chronic bacterial prostatitis (CBP).... A PubMed literature search on prostatitis was performed with no restrictions on publication date.... The epidemiology, pathophysiology, diagnosis, and treatment for ABP and CBP are explored using a clinical vignette as relevant context.... Bacterial prostatitis can be diagnosed through a focused history and microbiological investigations. The Meares-Stamey 4-glass test or modified 2-glass test can help confirm the diagnosis if uncertain...

Pharmacotherapeutic interventions for the treatment of bacterial prostatitis.

Bacterial prostatitis, acute or chronic, is one of the most prevalent urogenital infections in men. Its diagnosis requires the application of a careful methodology. Gram-negative bacilli are the most ... The aim of this article is to summarize the current evidence regarding the pathogenesis, etiology, empirical and definitive antimicrobial therapy, and new pharmacotherapeutic interventions to improve ... Bacterial prostatitis requires the application of an accurate diagnostic protocol to identify the causative agent and establish the optimal antimicrobial treatment. The structural and biochemical char...

Correlation of resistive index of prostatic capsular artery to clinical symptoms in men with chronic prostatitis/chronic pelvic pain syndrome.

To evaluate the relation between resistive index (RI) of prostatic capsular arteries by transrectal Doppler ultrasonography in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and its correl... In total, we included 68 patients presenting with chronic prostatitis/chronic pelvic pain syndrome. We formed two groups, as Group 1 of 35 patients with a RI ≥ 0.7 and Group 2 of 33 patients with RI <... Demographic characteristics were similar in the two groups. IPSS was 11.3 ± 6 in Group 1 and 9.7 ± 5.3 in Group 2. IIEF-5 was 18.6 ± 2 in Group 1 and 20.4 ± 2.3 in Group 2. PEDT was 12.4 ± 5.6 in Grou... There is a significant correlation between the lower urinary tract symptoms and erectile dysfunction parameters and the RI of the prostatic capsular artery in CP/CPPS and RI is an effective and noninv...

Does histological prostatic inflammation during transurethral resection of the prostate for bladder outlet obstruction affect post-operative urinary outcomes?

Benign prostate hyperplasia (BPH) is a common cause for bladder outlet obstruction (BOO) and lower urinary tract symptoms (LUTS) in men. The pathophysiology of BPH is multifactorial and inflammation h... Patients who had undergone TURP for BPH at a single institution between 2014 and 2018 were included. The study population was divided into three cohorts: those with no histological inflammation, those... A total 198 patients were included (no inflammation n = 101; any inflammation n = 97, prostatic stromal inflammation n = 81). All three groups were comparable in terms of baseline characteristics. The... Histological prostatitis is associated with worse urinary outcomes after TURP compared to no inflammation. These results are useful in improving prognostic discussions with patients after TURP....

Strong PD-L1 expression in granulomatous prostatitis.

The expression of programmed cell death ligand protein (PD-L1) is weakly investigated in non-tumoral and inflammatory prostatic pathology. The diagnosis of granulomatous prostatitis (GP) rests on the ... We studied PD-L1 expression in 17 GP cases (9 nonspecific GP, 5 Bacillus Calmette-Guérin induced prostatitis, 1 prostatic tuberculosis, and 3 cases of postsurgical prostatic granulomas). The control g... All of the GP cases showed easily visible strong membranous PD-L1 expression (high levels of combined positive score) in localized and diffuse epithelioid granulomatous prostatic inflammation. None of... The study presents the first attempt to examine PD-L1 expression in GP. Granulomatous inflammation in GP is easily identified when stained with PD-L1....